ReviewFrontiers in aging neuroscience2026
Corticotropin-releasing factor (CRF) in brain aging: from mitochondrial dysfunction to inflammaging.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a complex biological process. The corticotropin-releasing factor (CRF) signaling pathway has gained increasing attention for its potential role in regulating aging, acting as a key bridge connecting neuroendocrine stress mechanisms with both central and peripheral aging processes. As a core neuropeptide of the stress response, CRF primarily mediates downstream effects through its type 1 receptor (CRFR1), while its type 2 receptor (CRFR2) may play a modulatory, often opposing, role. Evidence from preclinical models indicates that excessive CRF signaling is associated with mitochondrial dynamics imbalance and biogenesis defects, leading to overproduction of reactive oxygen species (ROS) and mitochondrial DNA damage. These damaged mitochondria can subsequently release damage-associated molecular patterns (DAMPs), which activate innate immune pathways and may trigger a chronic low-grade inflammatory state, ultimately contributing to cellular senescence. Elucidating the cascading mechanisms by which CRF signaling could drive aging-from mitochondrial dysfunction to chronic inflammation-is essential for understanding the molecular basis of stress-accelerated aging. This review aims to systematically integrate research advances at the intersection of the CRF signaling pathway and aging hallmarks, focusing on a proposed "CRF-mitochondrial dysfunction-inflammation-aging" axis. We explore this regulatory network and its clinical translational potential to provide a theoretical foundation for unraveling the molecular mechanisms of stress-driven aging and identifying novel intervention targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.